GlassScriptPhysician profile
Justin Thomas Bates
NPI 1639852676
$5,687.88
in general payments reported to CMS, 2019-2025
17 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $640 · 2024: $2,452 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,663 · Education: $24.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,663.35 |
| Education | $24.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,893.08 | 2023-2025 | |
| Janssen Biotech, INC. | $1,095.60 | 2023-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $634.32 | 2024-2025 | Saphnelo |
| Ucb, INC. | $374.57 | 2023-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $280.55 | 2023-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $253.06 | 2024-2025 | Tremfya |
| Pfizer INC. | $216.83 | 2024-2025 | |
| Glaxosmithkline, LLC. | $208.71 | 2023-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $169.20 | 2023-2025 | |
| Amgen INC. | $153.10 | 2023-2025 | Evenity, Otezla, Krystexxa |
| Novo Nordisk INC | $125.00 | 2023 | Wegovy |
| Aurinia Pharma U.S., INC. | $70.08 | 2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $69.48 | 2024-2025 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $62.21 | 2024 | Arcalyst |
| Organon LLC | $32.49 | 2023 | Hadlima, Renflexis |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.07 | 2024 | Truxima |
| Celltrion USA INC. | $24.53 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.